A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Trial Profile

A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Feb 2018 Planned End Date changed from 1 Apr 2023 to 1 Sep 2027.
    • 01 Feb 2018 Planned primary completion date changed from 1 Apr 2023 to 1 Sep 2027.
    • 09 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top